MedTrace Logo

Chymase Angiotensin-(1-12) Axis In Hypertensive Disease

NCT05644769 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-12-09

No results posted yet for this study

Summary

Determine the presence of the human sequence of Angiotensin-(1-12) in plasma of ten untreated hypertensive subjects and after 4 week with Lisinopril 40 mg every day. Determine the blood pressure reduction with Lisinopril 40mg.

Conditions

Interventions

OTHER

Determine the presence of Human sequence Ang-(1-12) on no medication

Determine the presence of the human sequence of Ang-(1-12) in the plasma of ten normal male and female hypertensive patients on no medication.

DRUG

Human sequence Ang-(1-12) on Lisinopril 40mg every day

Determine the presence of the human sequence of Ang-(1-12) in the plasma of 10 normal male and female hypertensive patients after four weeks on Lisinopril 40 mg every day.

Sponsors & Collaborators

  • Wake Forest University Health Sciences

    collaborator OTHER

  • Trinity Hypertension & Metabolic Research Institute

    lead OTHER

Principal Investigators

  • Henry Punzi, MD · Trinity Hypertension & Metabolic Researach Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-15
Primary Completion
2023-03-31
Completion
2023-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05644769 on ClinicalTrials.gov